title: High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours.
abstract: The blood-brain barrier is a major obstacle for the chemotherapeutic drugs to effectively reach primary or secondary brain tumours. Stealth liposomal drugs are highly accumulated in tumoural tissues. In the present study we investigated the relative accumulation of(99m)Tc-DTPA radiolabelled stealth liposomal doxorubicin (Caelyx) in 10 patients with metastatic brain tumours and five patients with brain glioblastoma undergoing radiotherapy. Patients with metastatic brain lesions were treated with 10 consecutive fractions of radiotherapy (whole brain, 3 Gy/fraction, day 1-12) followed by a booster dose of 9 Gy (3 Gy/fraction, day 21-23). Caelyx, at a dose of 25 mg mg(-2)was given on day 1 and on day 21. Radiolabelled Caelyx accumulation was 13-19 times higher in the glioblastomas and 7-13 times higher in the metastatic lesions, as compared to the normal brain. The drug accumulation in the tumoural areas was 40-60% of the accumulation in the bone marrow of the skull bones. The normal brain radioactivity was <4% of the bone marrow, confirming an important shielding effect of the blood-brain barrier in the normal but not in the tumoural tissue. Four of 10 patients with metastatic lesions showed a complete response in CT-scan performed 2 months following therapy. There was no severe toxicity related to radiotherapy or to chemotherapy noted. It is concluded that stealth liposomal drugs selectively overcome the blood-brain barrier in the tumoural areas. The clinical importance of this observation is now under investigation.
authors.affiliation: Tumour and Angiogenesis Research Group, 18 Dimokratias Ave, Heraklior, Crete, 71306, Greece.
authors.forename: M I
authors.initials: MI
authors.lastname: Koukourakis
authors.forename: S
authors.initials: S
authors.lastname: Koukouraki
authors.forename: I
authors.initials: I
authors.lastname: Fezoulidis
authors.forename: N
authors.initials: N
authors.lastname: Kelekis
authors.forename: G
authors.initials: G
authors.lastname: Kyrias
authors.forename: S
authors.initials: S
authors.lastname: Archimandritis
authors.forename: N
authors.initials: N
authors.lastname: Karkavitsas
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001812:Blood-Brain Barrier; D001853:Bone Marrow / Q000737:chemistry; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary / Q000601:surgery; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D006801:Humans; D008081:Liposomes; D019275:Radiopharmaceuticals; D012886:Skull / Q000737:chemistry; D016284:Technetium Tc 99m Pentetate; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D019275:Radiopharmaceuticals; D004317:Doxorubicin; D016284:Technetium Tc 99m Pentetate